Curalin supplement as add-on therapy for type 2 diabetes Mellitus
Itamar Raz(Hebrew University of Jerusalem), Omri Segev(Tel Aviv University), Aliza Rozenberg(Hebrew University of Jerusalem), Saar Dor(Ben-Gurion University of the Negev), Ofer Yigdal(The Mofet Institute), Ilan Yanuv(Hebrew University of Jerusalem), Ron Elul(The Mofet Institute), Roni Weinberg Sibony(Rabin Medical Center)
Cited by 0
Related Papers
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
|The Lancet Diabetes & Endocrinology|2019|673
Overview of oxidative stress and inflammation in diabetes
|Journal of Diabetes|2024|216
Drug Therapies for Diabetes
|International Journal of Molecular Sciences|2023|99
Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the <scp>LEADER</scp> randomized trial
|Diabetes Obesity and Metabolism|2020|24